<DOC>
	<DOCNO>NCT00002333</DOCNO>
	<brief_summary>To compare safety , tolerance , efficacy saquinavir mesylate ( Ro 31-8959 ) alone , zalcitabine ( dideoxycytidine ; ddC ) alone , combination , patient discontinue unable take zidovudine ( AZT ) .</brief_summary>
	<brief_title>A Study Saquinavir Zalcitabine , Used Alone Together , Treatment Advanced HIV Infection Patients Who Stopped Taking Who Can Take Zidovudine</brief_title>
	<detailed_description>Patients randomize one three treatment regimen : ddC alone , Ro 31-8959 alone , ddC plus Ro 31-8959 . Treatment continue least 48 week . Patients stratify baseline CD4 count . ( Per 09/26/94 amendment , fourth arm , low dose Ro 31-8959 plus ddC , discontinue . )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : GCSF erythropoietin . Prophylaxis chronic suppression/maintenance therapy dapsone , aerosolized pentamidine , isoniazid , rifampin , fluoroquinolones , pyrazinamide , ethambutol , fluconazole , itraconazole , acyclovir , clotrimazole , nystatin , trimethoprim/sulfamethoxazole , pyrimethamine , folic acid , sulfadiazine , clindamycin , fansidar . Concurrent Treatment : Allowed : Limited localized radiation therapy skin . Patients must : Documented HIV infection . CD4 count 50 300 cells/mm3 . Received prior AZT discontinue least 28 day prior study entry . No active opportunistic infection require immediate treatment . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Signs symptoms peripheral neuropathy . Malabsorption inadequate oral intake ( define unable eat one meal daily chronic nausea , emesis , abdominal/oralesophageal discomfort . Malignancy , visceral Kaposi 's sarcoma , lymphoma require systemic chemotherapy and/or radiotherapy within next 48 week . Any grade 3 bad laboratory clinical abnormality . Inability comply protocol requirement . Concurrent Medication : Excluded : Other antiretroviral drug . Experimental drug . Nephrotoxic hepatotoxic drug . Drugs likely cause peripheral neuropathy . Antineoplastic agent . Biologic response modifier . Concurrent Treatment : Excluded : Radiation therapy limit localized therapy skin . Patients follow prior condition exclude : History nonHodgkin 's lymphoma . Unexplained fever &gt; = 38.5 C ( 101.5 F ) persist 14 day longer within 28 day prior study entry . Unexplained , chronic diarrhea ( defined 3 loose stool daily ) persist 14 day longer within 28 day prior study entry . History grade 2 bad peripheral neuropathy . Prior Medication : Excluded : Prior HIV proteinase inhibitor . Prior antiretroviral therapy AZT . Acute therapy opportunistic infection within 14 day prior study entry . Prior Treatment : Excluded : More 3 unit blood 21day period within 3 month prior study entry . Required : Prior AZT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1995</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
</DOC>